Supplementary Figure from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma
Zijun Y. Xu‐Monette(Duke University), Ken H. Young(Duke Medical Center), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Benjamin M. Parsons(Gundersen Health System), Maurilio Ponzoni(San Raffaele University of Rome), Eric D. Hsi(Mayo Clinic), Maher Albitar(Genomic Health (United States)), J. Han van Krieken(Radboud University Nijmegen), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), Heounjeong Go(Ulsan College), April Chiu(Mayo Clinic), Youli Zu(Methodist Hospital), Wayne Tam(Cornell University), Qingyan Au(NeoGenomics (United States)), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Xiaoping Sun(The University of Texas MD Anderson Cancer Center), Xiaosheng Fang(Shandong Provincial Hospital), Harry Nunns(NeoGenomics (United States)), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Yong Li(Baylor College of Medicine), Feng Zhu(Suzhou Kowloon Hospital), Bing Xu(Delft University of Technology), Xin Han(Chinese Academy of Sciences), Máté Nagy, Li Wei, Jane N. Winter(Northwestern University), Hua You(Third People's Hospital of Hangzhou), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k